USD
$0.00
(0.00%
)At Close (As of Sep 26, 2025)
$8.85B
Market Cap
16.93
P/E Ratio
4.37
EPS
$79.50
52 Week High
$42.01
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $856M |
Total Revenue | $1B |
Cost Of Revenue | $159M |
Costof Goods And Services Sold | $159M |
Operating Income | $551M |
Selling General And Administrative | $154M |
Research And Development | $79M |
Operating Expenses | $304M |
Investment Income Net | - |
Net Interest Income | -$18M |
Interest Income | - |
Interest Expense | $18M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $81M |
Income Before Tax | $557M |
Income Tax Expense | $113M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $444M |
Comprehensive Income Net Of Tax | - |
Ebit | $575M |
Ebitda | $657M |
Net Income | $444M |
Field | Value (USD) |
---|---|
Total Assets | $2.1B |
Total Current Assets | $1.1B |
Cash And Cash Equivalents At Carrying Value | $116M |
Cash And Short Term Investments | $116M |
Inventory | $142M |
Current Net Receivables | $308M |
Total Non Current Assets | $978M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $402M |
Intangible Assets Excluding Goodwill | $402M |
Goodwill | $417M |
Investments | - |
Long Term Investments | - |
Short Term Investments | $480M |
Other Current Assets | $39M |
Other Non Current Assets | - |
Total Liabilities | $1.7B |
Total Current Liabilities | $139M |
Current Accounts Payable | $10M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $1.6B |
Capital Lease Obligations | - |
Long Term Debt | $1.5B |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $1.5B |
Other Current Liabilities | $129M |
Other Non Current Liabilities | $55M |
Total Shareholder Equity | $364M |
Treasury Stock | - |
Retained Earnings | $360M |
Common Stock | $123K |
Common Stock Shares Outstanding | $129M |
Field | Value (USD) |
---|---|
Operating Cashflow | $479M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $81M |
Capital Expenditures | $11M |
Change In Receivables | - |
Change In Inventory | -$67M |
Profit Loss | - |
Cashflow From Investment | -$263M |
Cashflow From Financing | -$219M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$250M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $444M |
Field | Value (USD) |
---|---|
Gross Profit | $856M |
Total Revenue | $1B |
Cost Of Revenue | $159M |
Costof Goods And Services Sold | $159M |
Operating Income | $551M |
Selling General And Administrative | $154M |
Research And Development | $79M |
Operating Expenses | $304M |
Investment Income Net | - |
Net Interest Income | -$18M |
Interest Income | - |
Interest Expense | $18M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $81M |
Income Before Tax | $557M |
Income Tax Expense | $113M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $444M |
Comprehensive Income Net Of Tax | - |
Ebit | $575M |
Ebitda | $657M |
Net Income | $444M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Halozyme Therapeutics, Inc. is a leading biopharmaceutical technology company based in San Diego, California, specializing in innovative drug delivery solutions that enhance the efficacy of existing therapies. With a global presence across the United States, Europe, and Asia, Halozyme leverages its proprietary ENHANZE® technology to develop subcutaneous formulations for various indications, improving patient experience and compliance. The company collaborates with major pharmaceutical partners to expand its therapeutic portfolio, positioning itself as a pivotal player in the evolving landscape of biotechnology and drug administration.